{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T20:11:17Z","timestamp":1769890277345,"version":"3.49.0"},"reference-count":19,"publisher":"The Japan Society of Coloproctology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Anus Rectum Colon"],"published-print":{"date-parts":[[2026,1,25]]},"DOI":"10.23922\/jarc.2025-008","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T22:09:25Z","timestamp":1769292565000},"page":"169-177","source":"Crossref","is-referenced-by-count":0,"title":["Concomitant <i>RAS<\/i> and <i>BRAF<\/i> V600E Mutations in Unresectable Metastatic CRC: A Case of Long-term Survival"],"prefix":"10.23922","volume":"10","author":[{"given":"Kazuo","family":"Kitagawa","sequence":"first","affiliation":[{"name":"The Jikei University Kashiwa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"The Jikei University Kashiwa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Fukuda","sequence":"additional","affiliation":[{"name":"The Jikei University Kashiwa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Hannya","sequence":"additional","affiliation":[{"name":"The Jikei University Kashiwa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayumi","family":"Kurita","sequence":"additional","affiliation":[{"name":"The Jikei University Kashiwa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"The Jikei University Kashiwa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotaka","family":"Kumamoto","sequence":"additional","affiliation":[{"name":"The Jikei University Kashiwa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Toya","sequence":"additional","affiliation":[{"name":"The Jikei University Kashiwa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Eto","sequence":"additional","affiliation":[{"name":"The Jikei University Kashiwa Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10009","reference":[{"key":"1","unstructured":"1. Larki P, Gharib E, Yaghoob Taleghani M, et al. Coexistence of KRAS and BRAF mutations in colorectal cancer: A case report supporting the concept of tumoral heterogeneity. Cell J. 2017 Jun; 19 (Suppl 1): 113-7."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Afr\u0103s\u00e2nie VA, Gafton B, Marinca MV, et al. The coexistence of RAS and BRAF mutations in metastatic colorectal cancer: A case report and systematic literature review. J Gastrointestin Liver Dis. 2020 Jun; 29 (2): 251-6.","DOI":"10.15403\/jgld-1003"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Vittal A, Middinti A, Kasi LKA. Are all mutations the same? A rare case report of coexisting mutually exclusive KRAS and BRAF mutations in a patient with metastatic colon adenocarcinoma. Case Rep Oncol Med. 2017 Aug; 2017: 2321052.","DOI":"10.1155\/2017\/2321052"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ates O, Yalcin S. Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases. Indian J Cancer. 2019 Apr-Jun; 56 (2): 176-9.","DOI":"10.4103\/ijc.IJC_430_18"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Deshwar A, Margonis GA, Andreatos N, et al. Double KRAS and BRAF mutations in surgically treated colorectal cancer liver metastases: An international, multi-institutional case Series. Anticancer Res. 2018 May; 38 (5): 2891-5.","DOI":"10.21873\/anticanres.12535"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Vittal A, Sharma D, Samanta I, et al. Rare case of triple mutant (KRAS + NRAS + BRAF) metastatic colon adenocarcinoma. BMJ Case Rep. 2019 Sep; 12 (9): e221816.","DOI":"10.1136\/bcr-2017-221816"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015 Oct; 16 (13): 1306-15.","DOI":"10.1016\/S1470-2045(15)00122-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Satake H, Sunakawa Y, Miyamoto Y, et al. A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11. Oncotarget. 2018 Apr; 9 (27): 18811-20.","DOI":"10.18632\/oncotarget.24702"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep; 369 (11): 1023-34.","DOI":"10.1056\/NEJMoa1305275"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011 Oct 15; 117 (20): 4623-32.","DOI":"10.1002\/cncr.26086"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Vitiello PP, De Falco V, Giunta EF, et al. Clinical Practice Use of Liquid Biopsy to Identify RAS\/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. Cancers (Basel). 2019 Oct; 11 (10): 1504.","DOI":"10.3390\/cancers11101504"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Rachiglio AM, Sacco A, Lambiase M, et al. RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS\/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study. J Clin Oncol. 2023 May; 41 (16_suppl): 3046. doi:10.1200\/JCO.2023.41.16_suppl.3046","DOI":"10.1200\/JCO.2023.41.16_suppl.3046"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ueda K, Yamada T, Ohta R, et al. BRAF V600E mutations in right-side colon cancer: Heterogeneity detected by liquid biopsy. Eur J Surg Oncol. 2022 Jun; 48 (6): 1375-83.","DOI":"10.1016\/j.ejso.2022.01.016"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Xu T, Li J, Wang Z, et al. Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer. Cancer Med. 2023 May; 12 (9): 10473-84.","DOI":"10.1002\/cam4.5783"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Stahler A, Heinemann V, Ricard I, et al. Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials. J Cancer Res Clin Oncol. 2020 Aug; 146 (8): 2077-87.","DOI":"10.1007\/s00432-020-03290-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Cremolini C, Antoniotti C, Stein A, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020 Aug: JCO2001225.","DOI":"10.1200\/JCO.20.01225"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019 Oct; 381 (17): 1632-43.","DOI":"10.1056\/NEJMoa1908075"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013 Oct; 14 (11): 1077-85.","DOI":"10.1016\/S1470-2045(13)70154-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Prager GW, Taieb J, Fakih M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023 May; 388 (18): 1657-67.","DOI":"10.1056\/NEJMoa2214963"}],"container-title":["Journal of the Anus, Rectum and Colon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jarc\/10\/1\/10_2025-008\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:38:30Z","timestamp":1769834310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jarc\/10\/1\/10_2025-008\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,25]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.23922\/jarc.2025-008","relation":{},"ISSN":["2432-3853"],"issn-type":[{"value":"2432-3853","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,25]]},"article-number":"2025-008"}}